Molecular Mechanism of Tanshinone against Prostate Cancer
Prostate cancer (PCa) is the most common malignant tumor of the male urinary system in Europe and America. According to the data in the World Cancer Report 2020, the incidence rate of PCa ranks second in the prevalence of male malignant tumors and varies worldwide between regions and population grou...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/27/17/5594 |
| _version_ | 1797494094025457664 |
|---|---|
| author | Wei Li Tao Huang Shenghan Xu Bangwei Che Ying Yu Wenjun Zhang Kaifa Tang |
| author_facet | Wei Li Tao Huang Shenghan Xu Bangwei Che Ying Yu Wenjun Zhang Kaifa Tang |
| author_sort | Wei Li |
| collection | DOAJ |
| description | Prostate cancer (PCa) is the most common malignant tumor of the male urinary system in Europe and America. According to the data in the World Cancer Report 2020, the incidence rate of PCa ranks second in the prevalence of male malignant tumors and varies worldwide between regions and population groups. Although early PCa can achieve good therapeutic results after surgical treatment, due to advanced PCa, it can adapt and tolerate androgen castration-related drugs through a variety of mechanisms. For this reason, it is often difficult to achieve effective therapeutic results in the treatment of advanced PCa. Tanshinone is a new fat-soluble phenanthraquinone compound derived from Salvia miltiorrhiza that can play a therapeutic role in different cancers, including PCa. Several studies have shown that Tanshinone can target various molecular pathways of PCa, including the signal transducer and activator of transcription 3 (STAT3) pathway, androgen receptor (AR) pathway, phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway, and mitogen-activated protein kinase (MAPK) pathway, which will affect the release of pro-inflammatory cytokines and affect cell proliferation, apoptosis, tumor metabolism, genomic stability, and tumor drug resistance. Thus, the occurrence and development of PCa cells are inhibited. In this review, we summarized the in vivo and in vitro evidence of Tanshinone against prostate cancer and discussed the effect of Tanshinone on nuclear factor kappa-B (NF-κB), AR, and mTOR. At the same time, we conducted a network pharmacology analysis on the four main components of Tanshinone to further screen the possible targets of Tanshinone against prostate cancer and provide ideas for future research. |
| first_indexed | 2024-03-10T01:29:22Z |
| format | Article |
| id | doaj.art-1761cb5c40bb43fa8ec704bd1201d3f4 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T01:29:22Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-1761cb5c40bb43fa8ec704bd1201d3f42023-11-23T13:44:46ZengMDPI AGMolecules1420-30492022-08-012717559410.3390/molecules27175594Molecular Mechanism of Tanshinone against Prostate CancerWei Li0Tao Huang1Shenghan Xu2Bangwei Che3Ying Yu4Wenjun Zhang5Kaifa Tang6Department of Urology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, ChinaDepartment of Urology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, ChinaDepartment of Urology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, ChinaDepartment of Urology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, ChinaDepartment of Urology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, ChinaDepartment of Urology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, ChinaDepartment of Urology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, ChinaProstate cancer (PCa) is the most common malignant tumor of the male urinary system in Europe and America. According to the data in the World Cancer Report 2020, the incidence rate of PCa ranks second in the prevalence of male malignant tumors and varies worldwide between regions and population groups. Although early PCa can achieve good therapeutic results after surgical treatment, due to advanced PCa, it can adapt and tolerate androgen castration-related drugs through a variety of mechanisms. For this reason, it is often difficult to achieve effective therapeutic results in the treatment of advanced PCa. Tanshinone is a new fat-soluble phenanthraquinone compound derived from Salvia miltiorrhiza that can play a therapeutic role in different cancers, including PCa. Several studies have shown that Tanshinone can target various molecular pathways of PCa, including the signal transducer and activator of transcription 3 (STAT3) pathway, androgen receptor (AR) pathway, phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway, and mitogen-activated protein kinase (MAPK) pathway, which will affect the release of pro-inflammatory cytokines and affect cell proliferation, apoptosis, tumor metabolism, genomic stability, and tumor drug resistance. Thus, the occurrence and development of PCa cells are inhibited. In this review, we summarized the in vivo and in vitro evidence of Tanshinone against prostate cancer and discussed the effect of Tanshinone on nuclear factor kappa-B (NF-κB), AR, and mTOR. At the same time, we conducted a network pharmacology analysis on the four main components of Tanshinone to further screen the possible targets of Tanshinone against prostate cancer and provide ideas for future research.https://www.mdpi.com/1420-3049/27/17/5594prostate cancerTanshinonemTORApoptosisNF-κB |
| spellingShingle | Wei Li Tao Huang Shenghan Xu Bangwei Che Ying Yu Wenjun Zhang Kaifa Tang Molecular Mechanism of Tanshinone against Prostate Cancer Molecules prostate cancer Tanshinone mTOR Apoptosis NF-κB |
| title | Molecular Mechanism of Tanshinone against Prostate Cancer |
| title_full | Molecular Mechanism of Tanshinone against Prostate Cancer |
| title_fullStr | Molecular Mechanism of Tanshinone against Prostate Cancer |
| title_full_unstemmed | Molecular Mechanism of Tanshinone against Prostate Cancer |
| title_short | Molecular Mechanism of Tanshinone against Prostate Cancer |
| title_sort | molecular mechanism of tanshinone against prostate cancer |
| topic | prostate cancer Tanshinone mTOR Apoptosis NF-κB |
| url | https://www.mdpi.com/1420-3049/27/17/5594 |
| work_keys_str_mv | AT weili molecularmechanismoftanshinoneagainstprostatecancer AT taohuang molecularmechanismoftanshinoneagainstprostatecancer AT shenghanxu molecularmechanismoftanshinoneagainstprostatecancer AT bangweiche molecularmechanismoftanshinoneagainstprostatecancer AT yingyu molecularmechanismoftanshinoneagainstprostatecancer AT wenjunzhang molecularmechanismoftanshinoneagainstprostatecancer AT kaifatang molecularmechanismoftanshinoneagainstprostatecancer |